These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 10501914

  • 1. Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243).
    Sessa C, Zucchetti M, Ghielmini M, Bauer J, D'Incalci M, de Jong J, Naegele H, Rossi S, Pacciarini MA, Domenigoni L, Cavalli F.
    Cancer Chemother Pharmacol; 1999; 44(5):403-10. PubMed ID: 10501914
    [Abstract] [Full Text] [Related]

  • 2. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
    Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, Jones S, Woodworth JR, Baker S, Langley C, Mascorro D, Abrahams T, Von Hoff DD.
    Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
    [Abstract] [Full Text] [Related]

  • 3. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla JP, Négrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C.
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
    Planting AS, Sonneveld P, van der Gaast A, Sparreboom A, van der Burg ME, Luyten GP, de Leeuw K, de Boer-Dennert M, Wissel PS, Jewell RC, Paul EM, Purvis NB, Verweij J.
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
    [Abstract] [Full Text] [Related]

  • 6. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL, Rowinsky EK, Hammond LA, Weiss GR, Hidalgo M, Clark GM, Moczygemba J, Choi L, Linnartz R, Barbet NC, Sklenar IT, Capdeville R, Gan G, Porter CW, Von Hoff DD, Eckhardt SG.
    Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
    [Abstract] [Full Text] [Related]

  • 7. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [Abstract] [Full Text] [Related]

  • 8. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL, Tseng YL.
    Cancer; 2001 May 01; 91(9):1826-33. PubMed ID: 11335910
    [Abstract] [Full Text] [Related]

  • 9. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
    Li S, Huang H, Liao H, Zhan J, Guo Y, Zou BY, Jiang WQ, Guan ZZ, Yang XQ.
    Int J Clin Pharmacol Ther; 2013 Feb 01; 51(2):96-105. PubMed ID: 23127487
    [Abstract] [Full Text] [Related]

  • 10. A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.
    Fokkema E, Verweij J, van Oosterom AT, Uges DR, Spinelli R, Valota O, de Vries EG, Groen HJ.
    Br J Cancer; 2000 Feb 01; 82(4):767-71. PubMed ID: 10732743
    [Abstract] [Full Text] [Related]

  • 11. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I, Bench K, Beijnen JH, Bruntsch U, Cavalli F, de Jong J, Groot Y, van Tellingen O, Wanders J, Sessa C.
    Clin Cancer Res; 1996 Oct 01; 2(10):1717-23. PubMed ID: 9816122
    [Abstract] [Full Text] [Related]

  • 12. Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762).
    Vasey PA, Bissett D, Strolin-Benedetti M, Poggesi I, Breda M, Adams L, Wilson P, Pacciarini MA, Kaye SB, Cassidy J.
    Cancer Res; 1995 May 15; 55(10):2090-6. PubMed ID: 7743508
    [Abstract] [Full Text] [Related]

  • 13. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
    Toffoli G, Sorio R, Aita P, Crivellari D, Corona G, Bearz A, Robieux I, Colussi AM, Stocco F, Boiocchi M.
    Clin Cancer Res; 2000 Jun 15; 6(6):2279-87. PubMed ID: 10873078
    [Abstract] [Full Text] [Related]

  • 14. Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study.
    Roh JK, Rha SY, Lee CI, Lee KH, Lee JJ, Shim HJ, Lee SD, Kim WB, Yang J, Kim SH, Lee MG.
    Int J Clin Pharmacol Ther; 1998 Jun 15; 36(6):312-9. PubMed ID: 9660038
    [Abstract] [Full Text] [Related]

  • 15. PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study.
    Groen HJ, de Vries EG, Wynendaele W, van der Graaf WT, Fokkema E, Lechuga MJ, Poggesi I, Dirix LY, van Oosterom AT.
    Clin Cancer Res; 2001 Dec 15; 7(12):3928-33. PubMed ID: 11751484
    [Abstract] [Full Text] [Related]

  • 16. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B, Takimoto CH, Goetz A, Diab S, Hammond LA, Smetzer L, Schwartz G, Gazak R, Callaghan JT, Von Hoff DD, Rowinsky EK.
    Clin Cancer Res; 2003 Nov 15; 9(15):5540-9. PubMed ID: 14654534
    [Abstract] [Full Text] [Related]

  • 17. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
    Lockhart AC, Bukowski R, Rothenberg ML, Wang KK, Cooper W, Grover J, Appleman L, Mayer PR, Shapiro M, Zhu AX.
    Cancer Chemother Pharmacol; 2007 Jul 15; 60(2):203-9. PubMed ID: 17091249
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K, Nakagawa K, Kurata T, Satoh T, Nogami T, Takeda K, Mitsuoka S, Yoshimura N, Kudoh S, Negoro S, Fukuoka M.
    Cancer Chemother Pharmacol; 2007 Jul 15; 60(2):285-93. PubMed ID: 17136542
    [Abstract] [Full Text] [Related]

  • 19. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.
    Madden T, Tran HT, Beck D, Huie R, Newman RA, Pusztai L, Wright JJ, Abbruzzese JL.
    Clin Cancer Res; 2000 Apr 15; 6(4):1293-301. PubMed ID: 10778954
    [Abstract] [Full Text] [Related]

  • 20. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
    Cunningham C, Appleman LJ, Kirvan-Visovatti M, Ryan DP, Regan E, Vukelja S, Bonate PL, Ruvuna F, Fram RJ, Jekunen A, Weitman S, Hammond LA, Eder JP.
    Clin Cancer Res; 2005 Nov 01; 11(21):7825-33. PubMed ID: 16278405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.